tirzepatide used for New Access and Pricing Through Self-Pay Options The promise of tirzepatide: A

Rate of weight loss

These structural modifications significantly reduce IGF-1s binding affinity to IGF-binding proteins (IGFBPs), increasing the availability of the active peptide during in-vitro experimentation

Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions

Other sought-after benefits include energy boost (39%), immunity (33%), enhanced sleep or rest (32%) and cognitive enhancement (20%).